From: Ventricular assist devices as bridge to heart transplantation: impact on post-transplant infections
Bacterial and candida infection | All fungal infections | Viral infections | |||||||
---|---|---|---|---|---|---|---|---|---|
Hazard ratio | 95 % CI | p-value | Hazard ratio | 95 % CI | p-value | Hazard ratio | 95 % CI | p-value | |
Recipient agea | 0.89 | 0.67-1.19 | 0.43 | 1.30 | 0.77-2.21 | 0.32 | 0.91 | 0.68-1.20 | 0.49 |
Recipient male gender | 2.06 | 0.85-5.01 | 0.11 | 0.98 | 0.22-4.32 | 0.98 | 1.59 | 0.62-4.10 | 0.33 |
Donor agea | 1.03 | 0.81 – 1.31 | 0.81 | 1.10 | 0.74 – 1.63 | 0.64 | 0.92 | 0.70 – 1.20 | 0.54 |
Donor male gender | 1.88 | 0.91 – 3.89 | 0.09 | 0.76 | 0.27 – 2.20 | 0.62 | 0.50 | 0.23 – 1.06 | 0.07 |
VAD pre-transplant | 0.27b | 0.06-1.30 | 0.10 | ||||||
- Continuous-flow device | 0.94 | 0.38- 2.32 | 0.89 | 0.91 | 0.32 – 2.56 | 0.86 | |||
- Other device | 0.45 | 0.15 - 1.34 | 0.15 | 0.64 | 0.18 – 2.22 | 0.48 | |||
Diabetes | 1.48 | 0.69-3.20 | 0.32 | 2.74 | 0.87-8.57 | 0.08 | 2.01 | 0.82-5.31 | 0.12 |
Post-transplant cotrimoxazole prophylaxis | 0.29 | 0.15-0.57 | <0.001 | 1.04 | 0.36-3.01 | 0.95 | 1.03 | 0.49-2.17 | 0.94 |
Transplant center | |||||||||
Center A (ref.) | 1 | 1 | 1 | ||||||
Center B | 0.69 | 0.32 – 1.49 | 0.35 | 1.38 | 0.40-4.78 | 0.61 | 1.06 | 0.46-2.45 | 0.89 |
Center C | 0.55 | 0.23 – 1.31 | 0.18 | 0.28 | 0.04-1.78 | 0.18 | 0.50 | 0.18-1.44 | 0.20 |
Induction therapy | |||||||||
No induction(ref.) | 1 | 1 | 1 | ||||||
ATG | 1.01 | 0.35 – 2.96 | 0.98 | 0.18 | 0.02-1.37 | 0.10 | 1.20 | 0.34-4.25 | 0.78 |
Basiliximab | 1.57 | 0.42 – 5.92 | 0.50 | 0.40 | 0.03-5.58 | 0.50 | - | - | - |
Use of everolimus | 0.34 | 0.08 – 1.49 | 0.15 | 2.24 | 0.54-9.33 | 0.27 | 0.90 | 0.28-2.86 | 0.86 |